NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TORONTO, ONTARIO - October 22, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.

The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS.

The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release.

Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term.

SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs.

About NeuroThera Labs Inc.

NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty
IR Manager
NeuroThera Labs Inc.
Telephone: +972-3-7617108
Email: [email protected]

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release.

Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca).

The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome.